Clinical trials: Substance Abuse Detection
Healthy Volunteers
Bioavailability Study of Fexofenadine HCl New Formulation Tablet
The purpose of the study is to assess the relative bioavailability of a new galenic form of fexofenadine HCl new formulation tablet (test drug) taken with or without water compared to fexofenadine HCl film-coated tablets…
- Trial name
- NCT06284902
- Testing
- Fexofenadine HCl Coated tablet, Fexofenadine HCl New Formulation Tablet
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Opella Healthcare Group SAS, a Sanofi Company
Neoplasms
First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients
This research study is looking at a new DARPin® drug candidate, called MP0250. There is evidence from preclinical studies that MP0250 may be effective in the treatment of cancer.
- Trial name
- NCT02194426
- Testing
- MP0250
- Where
- 4 sites in Spain, Switzerland and 1 more
- Volunteers
- 58 people
- Sponsor
- Molecular Partners AG
Alcohol Use Disorder, Alcohol Dependence
Tech-Enabled CM for AUD at Scale
This Phase II Small Business Innovative Research (SBIR) project is a clinical effectiveness and cost-effectiveness random controlled trial (RCT) of DynamiCare Health's innovative smartphone/smart debit card remote digital…
- Conditions
- Alcohol Use Disorder, Alcohol Dependence, Drug Dependence
- Trial name
- NCT04581499
- Testing
- DynamiCare Motivation Support Program, Untreated or Routine Care Control Group
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- DynamiCare Health
Bioequivalence
Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg
The primary aim of this study is to demonstrate bioequivalence in the rate and extent of absorption between 1600 μg selexipag test drug (administered orally as film-coated tablets of 1600 μg, twice a day (b.i.d.) and 1600 μg…
- Trial name
- NCT02206295
- Testing
- selexipag
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Actelion
Neuralgia, Postherpetic, Diabetic Neuropathy
Neuropathic Pain Syndrome Patient Study (MK-0000-072)
The purpose of this study is to determine the best way to conduct clinical trials in patients with neuropathic pain (nerve pain). This study will see if generic pregabalin has any effect on neuropathic pain.
- Conditions
- Neuralgia, Postherpetic, Diabetic Neuropathy, Painful Small-Fiber Neuropathy, Idiopathic Distal Sensory Polyneuropathy
- Trial name
- NCT00570310
- Testing
- Comparator: pregabalin
- Volunteers
- 104 people
- Sponsor
- Merck Sharp & Dohme LLC
Nebulizers and Vaporizers
Explorative Clinical Investigation to Investigate the Ability of PreciseInhale to Direct Regional Lung Targeting and Reduce the Degree of Throat Deposition and Subsequent Gastrointestinal Absorption in Healthy Volunteers After Inhalation of Test Drug Substances Via the PreciseInhale System
This is a single site, open label, 4-inhalation sessions, explorative clinical investigation to investigate the ability of PreciseInhale to direct regional lung targeting and reduce the degree of throat deposition and subsequent…
- Trial name
- NCT04946630
- Testing
- PreciseInhale, Seretide Evohaler forte
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Inhalation Sciences Sweden AB
Substance Abuse Detection
Risk of Shopping Behavior of Tapentadol Immediate-Release (IR) Compared to Oxycodone Immediate-Release (IR)
The purpose of this study is to compare the risk of shopping behavior of tapentadol immediate release with the risk of shopping behavior of oxycodone immediate release.
- Trial name
- NCT01545778
- Testing
- Tapentadol IR, Oxycodone IR
- Volunteers
- 646,620 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cannabis Intoxication
Cannabis Impairment Detection Device Study
The goal of this study is to develop a cannabis impairment detection device in adult cannabis users. The main question[s] it aims to answer are: Is the investigational device accurate and reliable at detecting cannabis…
- Trial name
- NCT07122349
- Testing
- Cannabis Impairment Test
- Where
- Canada
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Gaize
Driving Under the Influence, Marijuana Intoxication
Cannabis Impairment Detection Application (CIDA)
Subjects will participate in a 4-visit study protocol in which they will be asked to complete a set of computerized tasks and a 45-minute simulated drive in a driving simulator.
- Conditions
- Driving Under the Influence, Marijuana Intoxication, Alcohol Intoxication
- Trial name
- CIDA (NCT04230460)
- Testing
- Cannabis (High% THC) (Inhaled), Cannabis (Very High% THC) (Inhaled), Alcohol (oral)
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Advanced Brain Monitoring, Inc.
Target Drug-related Adverse Events
Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens
The purpose of this study is to determine whether the addition of selective pharmacogenomic (PGx) testing as determined by Urine Drug Testing (UDT) adds a clinical benefit as evidenced by a reduction in Target Drug-related…
- Trial name
- SPHERE (NCT02625155)
- Testing
- Urine diagnostic testing as SOC, drug regimen changes per SOC, Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results
- Where
- United States
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- InSource Diagnostics
Colorectal Neoplasms
MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer
The purpose of the study is to determine the feasibility of generating sufficient MicroOrganoSpheres (MOS) from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and completing a…
- Trial name
- MODEL-CRC (NCT05189171)
- Testing
- MicroOrganoSphere (MOS) drug screen
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- Xilis, Inc.
Breast Neoplasms, Lung Neoplasms
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
DiaTech is a private company performing patient specific cancer chemosensitivity testing for patients and physicians. DiaTech Oncology is doing this clinical study to see if an experimental new technology called the microculture…
- Conditions
- Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma, Soft Tissue
- Trial name
- NCT00243685
- Testing
- Laboratory Assay, Mick Assay
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Pierian Biosciences
Asthma
Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma
The primary objective of the study is to evaluate the anti-inflammatory action and safety of Ro 27-2441 (study drug) in asthmatic patients currently taking inhaled corticosteroids.
- Trial name
- NCT00048022
- Testing
- Dual Integrin Antagonist
- Where
- 60 sites in United States, Puerto Rico
- Sponsor
- Hoffmann-La Roche
Asthma
Evaluation of Various Doses of Ro 27-2771 (Test Drug) in Asthmatic Patients Not Treated With Inhaled Corticosteroids
The purpose of this study is to determine the appropriate dose of Ro 27-2441 (test drug) to be used in future studies, assess the efficacy and safety, and the anti-inflammatory action of the test drug in the treatment of…
- Trial name
- NCT00048009
- Testing
- Dual Integrin Antagonist
- Where
- 91 sites in United States, Australia and 3 more
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
This study will evaluate the effectiveness of fostamatinib (200 mg twice a day) in patients with worsening or unmanageable lymphoma with a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (abbreviated as DLBCL)
- Trial name
- NCT01499303
- Testing
- Fostamatinib
- Where
- 21 sites in United States, United Kingdom
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Gout
Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.
To assess the bioequivalence between lesinurad/allopurinol 200/300 FDC tablets and coadministered lesinurad and allopurinol tablets in the fasted state based on the pharmacokinetic (PK) evaluation of lesinurad and allopurinol in…
- Trial name
- NCT03272425
- Testing
- lesinurad/allopurinol 200/300 FDC tablets, lesinurad 200 mg, allopurinol 300 mg
- Where
- Brazil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ardea Biosciences, Inc.
Hypolactasia
A Non-inferiority, Multicenter and Randomized, Single-Dose Study About a Treatment to Hypolactasia (LAILAI)
The study primary objective is to compare the clinical efficacy of two formulations in the supportive treatment of lactose intolerance.
- Trial name
- EF099 (NCT01145339)
- Testing
- Lactase
- Where
- 7 sites in Brazil
- Volunteers
- 140 people
- Sponsor
- Eurofarma Laboratorios S.A.
Neoplasms
Investigation of Mass Balance of the Test Drug and Major Metabolites
The purpose of this study is to: a) Determine how the body takes up the test drug and distributes it into various body organs and tissues, how it processes the drug and how it ultimately removes it; and b) Examine how well the…
- Trial name
- NCT00432302
- Testing
- Sagopilone (BAY 86-5302, ZK 219477)
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Bayer
Dry Eye Syndromes
Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients
This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56 5%) compared to control drug(vehicle) in Patients with Dry Eye Disease.
- Trial name
- NCT06291194
- Testing
- AJU-S56 5%
- Where
- South Korea
- Volunteers
- 396 people
- Sponsor
- AJU Pharm Co., Ltd.